Recent Company News

• 05:09 PM ET Dec 16, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 05:42 PM ET Dec 15, 2025
  

  Allogene Therapeutics reports on result for Servier in arbitration with Cellectis ($1.47, 0.00)

• 04:54 PM ET Dec 15, 2025
  

  Cellectis SA announces arbitral decision in dispute with Servier (€4.11, 0.00)

• 04:21 AM ET Dec 08, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:53 AM ET Dec 08, 2025
  

  StreetAccount Summary - European pre-market trading update

• 01:34 AM ET Dec 08, 2025
  

  Cellectis announces presentation of encouraging updated data of patients treated in the Phase 1 NATHALI-01 clinical trial with eti-cel, at the 67th Annual Meeting of ASH (€4.12, 0.00)

• 05:51 AM ET Nov 25, 2025
  

  StreetAccount Summary - European unusual volume traders

• 09:18 AM ET Nov 19, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 06:29 AM ET Nov 19, 2025
  

  Cellectis announces publication of article in Nature Communications on a non-viral gene editing process enabling efficient gene insertion in HSPCs (€3.84, +0.27)